S_ry Clinical data were reviewed in 325 patients with prostatic adenocarcinoma followed up for a mean of 13 years. Paraffin-embedded tumour biopsy specimens from the primary tumours were available for flow cytometry (FCM) in 273 cases. Intra-tumour heterogeneity in DNA index (DI) was found in 4% of the tumours (54 cases were analysed). S-phase fraction (SPF) and DNA ploidy were significantly interrelated. Aneuploidy and high SPF were significantly related to both a high T category and high Gleason score. The progression in TI -2M0 tumours was related to Gleason score (P= 0.009 Prostatic adenocarcinoma is the most common malignancy among elderly men, although only a small fraction of the tumours progress to metastatic disease. The latent cancer is 3-8 times more common than the clinical form of the disease. Accordingly, identification of the malignant subset of prostatic tumours would be of great help in planning treatment and follow-up strategies for the ever-increasing number of men suffering from this age-related disease (Muir et al., 1991) . Currently, the prognostic evaluation of prostatic adenocarcinoma is based on tumour staging (UICC, 1978) and on subjective histological grading. Currently, there are several different grading systems for prostatic adenocarcinoma, and most correlate with prognosis (Mostofi, 1975; Gleason 1977; Gaeta et al., 1980) . DNA flow cytometry (FCM) provides more objetive prognostic information than grading in several human tumours (Frierson, 1991; Deitch & DeVere White 1992; Lipponen et al., 1993) and measurement of the S-phase fraction (SPF) has given prognostic estimates superior to DNA ploidy alone (Frierson, 1991; Visakorpi et al., 1991; Lipponen et al., 1993). From previous studies we know that DNA ploidy correlates with the histological grade in prostatic adenocarcinoma (Badalament et al., 1991; Robertson & Paulson 1991; Visakorpi et al., 1991; Di Silvero et al., 1992) 
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SPF was significantly related to T and M categories so that T3-4 tumours and tumours with distant metastasis had high SPFs. Tumours with high Gleason scores also had a high SPF (Table II) . DNA ploidy and SPF were independent of patient age (P>0.5).
In univariate survival analysis, T category (Figure 1 (Table III) .
In the survival analysis of Tl-2M0 tumours, Gleason score (X2 = 13.4, P= 0.0013), DNA ploidy ( Figure 5 ) and SPF ( Figure 6 ) were significantly related to prognosis. In patients with diploid TIMO tumours (n = 84) the 10 year survival was 85%, in contrast to 65% in patients with aneuploid tumours (n = 14) (X2= 4.8, P = 0.026). The SPF showed a nonsignificant trend (X2=2.3, P=0.12). Tumours with a Gleason score of 5-7 could be separated into two prognostic groups on the basis of DNA ploidy (x2=4.0, P=0.0439) and median SPF (5%) (X2= 11.5, P = 0.0007). In patients with Ti -2MO tumours with Gleason score 5-7, the 10 year survival was 90% in those with diploid tumours (n = 84), and 45% in those with aneuploid tumours (n = 18, x2 = 14.9, P = 0.0001). The survival of patients with an SPF below the median value of 5% (n = 72) was 90%, and of those with an SPF above the median (n = 28) was only 50% (,e = 14.4, P = 0.0001).
We defined a two-category system for prostatic adenocarcinoma in which Gleason score 2-4 and Gleason score 5-7 tumours with a diploid DNA histogram or SPF lower than 5% were combined into category A(1). Gleason score 8-10 tumours and the rest of Gleason score 5-7 tumours with aneuploid DI or an SPF above the median were combined into category A(2). The results of a survival analysis using this system (Table IV) prognostic information in addition to T and M categories ( (P= 0.066), but if the Gleason score was not used in the analysis SPF was included among the independent predictors (P = 0.07). In patients treated by transurethral resection M category (P<0.001), patient age (P = 0.021) and T category (P = 0.038) had independent prognostic value. In those patients subjected to active surveillance, T category (P = 0.002) and DNA ploidy (P = 0.02) were independent prognostic factors. If all the types of therapy were entered in multivariate analysis as binary data (yes/no), oestrogen therapy (P = 0.051) and orchiectomy (P = 0.059) resulted in Table IV. lowered survival probability, while other types of therapy had no independent prognostic significance.
Heterogeneity of DNA indices is a common feature of malignant neoplasms. (Kallioniemi, 1988; Lipponen et al., 1993) , although up to 90% of lung tumours may show heterogeneous DNA indices (Carey et al., 1990) . A high proportion of prostatic adenocarcinomas have been reported to have heterogeneous DNA indices in image cytometry (Nagel & Al-Abadi, 1991) .
In the present FCM analysis only 4% of the tumours showed intra-tumour variability in DI, and the mean variation of SPF within a tumour was also low. Accordingly, the results suggest that intra-tumour heterogeneity of DNA ploidy and SPF is a rare phenomenon in prostatic adenocarcinoma, in contrast to several other epithelial neoplasms (Kallioniemi, 1988; Carey et al., 1990; Fern6 et al., 1992; Lipponen et al., 1993 DNA aneuploidy was related to invasive high-grade disease, which is in agreement with previous reports in prostatic adenocarcinoma (Jones et al., 1990; Tribukait, 1991; Visakorpi et al., 1991; Di Silvero et al., 1992 Tnrbukait, 1991) , while the fraction of tumours with multiple cell lines was clearly lower than in some previous reports (Tribukait, 1991) . However, there was no difference in the prognostic value between various levels of aneuploidy, as reported by some investigators (Hedlund et al., 1988; Tribukait, 1991) . The present results are in accord with the results in other epithelial carcinomas (Frierson, 1991; Lipponen et al., 1993) . in which the degree of aneuploidy as measured by flow cytometry had no additional prognostic value.
The SPF values were similar in Tru-cut biopsy specimens and in surgical or transurethral resection specimens, and accordingly the type of specimen was not a significant confounding factor, although Fassa et al. (1992) reported some differences in FCM results in different types of biopsy. Aneuploid tumours showed significantly higher SPF values than the diploid tumours, which is in accord with previous results Visakorpi et al., 1991) . The degree of aneuploidy had little influence on SPF value, which further supports the limited prognostic value of the degree of aneuploidy. In addition, the clinical correlations in this analysis and in previous reports Visakorpi et al., 1991) suggest that the SPF is a more important prognostic indicator than ploidy. In other epithelial tumours, the proliferation rate of cancer cells has been included, in addition to clinical stage, among the independent predictors (Frierson, 1991; Lipponen et al., 1993) . The proliferation of cells is regulated through specific genes (Visakorpi et al., 1992) , and aneuploidy may be a reflection of genetic instability rather than proliferative potential.
Histopathological grading has been shown to correlate with stage and prognosis in prostatic adenocarcinoma (Mostofi, 1975; Gleason, 1977; Oesterling et al., 1987; Badalament et al., 1991; Visakorpi et al., 1991) . However, tumours with intermediate differentiation are biologically heterogeneous (Nagel & Al-Abadi, 1991) , and accordingly the prognosis of patients with these tumours is also variable. In this analysis, tumours with Gleason scores 5-7 could be regrouped into distinctly different prognostic groups by FCM, which suggests a clinical application for FCM in prostatic adenocarcinoma. The importance of this classification could be confirmed in multivariate analysis, which clearly showed that neither the original Gleason score nor FCM data were included among the independent predictors. Tumours with Gleason scores of 2-4 or 8-10 could not be subdivided into prognostic groups by determining DI or SPF, since nearly all the low-score tumours are diploid and the high-score tumours aneuploid. This association is reflected also in the results of analysis of T3-4 tumours, which could not be regrouped. The combined use of quantitative measurements and subjective histological assessment has been previously tested in transitional cell bladder tumours with similar results (Lipponen et al., 1992) .
Although patient age and malignant histological features (Gleason score, Di, SPF, clinical stage) were not significantly interrelated, patient age was an independent prognostic factor in all T3-4 tumours. This suggests that compromised general physical condition and reduced capacity to resist tumour growth are of importance, as has been observed in other neoplastic diseases (Aaltomaa et al., 1991) . Most of the previous survival analyses performed in prostatic carcinoma have not considered age as a prognostic factor (Stephenson et al., 1987; Badalament et al., 1991; Nagel & Al-Abadi, 1991; Tribukait, 1991; Di Silvero et al., 1992; Peter-Gee et al., 1992) , and accordingly the comparison of results based on biological variables alone is difficult. The year of treatment was included in the multivariate analysis but did not relate to prognosis.
To test the possibility that the type of therapy might influence the prognosis, therapy was included in separate multivanate analyses, which showed that none of the therapies improved the prognosis in relation to clinical, histological and FCM parameters. In contrast, hormonal therapy was related to an unfavourable prognosis, which is probably because of the preferential use of hormones in patients with disseminated disease. Separate analyses of three major therapy groups (hormones, electroresection, active surveillance) showed that the same parameters had independent prognostic significance as in the entire cohort. Accordingly, the results of these analyses suggest that the biological characteristics of prostatic tumours are most important for the outcome of the patients.
In summary, we conclude that DNA aneuploidy and a high SPF are related to a malignant phenotype in prostatic adenocarcinomas. In practice, FCM can be used to subdivide tumours with Gleason scores of 5-7 into subgroups with different prognoses. The combination of FCM, conventional histological grading and clinical or histological staging provides accurate prognostic information in prostatic adenocarcinomas.
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